Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FS102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| FS102 | EXPERIMENTAL | Dose escalation of either weekly or Q3W of FS102 |
| Name | Type | Description |
|---|---|---|
| FS102 | DRUG | Experimental |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: 1. Signed written informed consent obtained prior to performing any study procedure, including screening procedures. 2. Men and women ≥ 18-years-old on the day of signing infor...
FS102 is an investigational small molecule being studied for the treatment of solid tumors that overexpress HER2, also known as HER2 positive solid tumors. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
FS102 targets HER2, a protein that is overexpressed in certain solid tumors. By targeting HER2, FS102 is designed to interfere with the signaling pathways that drive tumor growth in HER2 positive cancers.
FS102 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY.
FS102 is in Phase 1 clinical development. A Phase 1 multiple ascending dose study has been completed, and the drug remains investigational, meaning it has not been approved by regulatory authorities.
FS102 has one completed clinical trial, identified as NCT02286219. This was a Phase 1, multiple ascending dose study of anti-HER2 FCAB FS102 in HER2 positive solid tumors, conducted in the United States and Canada with 30 participants.
Yes, FS102 is also referred to as anti-HER2 FCAB in clinical trial documentation. The completed study NCT02286219 is titled 'Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors'.